CA2815506C - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride - Google Patents

Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride Download PDF

Info

Publication number
CA2815506C
CA2815506C CA2815506A CA2815506A CA2815506C CA 2815506 C CA2815506 C CA 2815506C CA 2815506 A CA2815506 A CA 2815506A CA 2815506 A CA2815506 A CA 2815506A CA 2815506 C CA2815506 C CA 2815506C
Authority
CA
Canada
Prior art keywords
ponatinib
ponatinib hydrochloride
solvent
hydrochloride
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2815506A
Other languages
English (en)
French (fr)
Other versions
CA2815506A1 (en
Inventor
Christopher K. Murray
Leonard W. Rozamus
John J. Chaber
Pradeep Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2815506(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Priority to CA3022250A priority Critical patent/CA3022250A1/en
Publication of CA2815506A1 publication Critical patent/CA2815506A1/en
Application granted granted Critical
Publication of CA2815506C publication Critical patent/CA2815506C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2815506A 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride Active CA2815506C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3022250A CA3022250A1 (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US61/736,543 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US61/737,007 2012-12-13
US201361788208P 2013-03-15 2013-03-15
US61/788,208 2013-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3022250A Division CA3022250A1 (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Publications (2)

Publication Number Publication Date
CA2815506A1 CA2815506A1 (en) 2014-06-12
CA2815506C true CA2815506C (en) 2018-12-11

Family

ID=50929140

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2815506A Active CA2815506C (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CA3022250A Abandoned CA3022250A1 (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CA3167093A Pending CA3167093A1 (en) 2012-12-12 2013-05-09 Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3022250A Abandoned CA3022250A1 (en) 2012-12-12 2013-05-09 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
CA3167093A Pending CA3167093A1 (en) 2012-12-12 2013-05-09 Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Country Status (9)

Country Link
US (9) US9493470B2 (enExample)
JP (5) JP6447508B2 (enExample)
CN (2) CN105188701A (enExample)
CA (3) CA2815506C (enExample)
CL (1) CL2015001643A1 (enExample)
HK (1) HK1218878A1 (enExample)
MX (11) MX391445B (enExample)
NZ (1) NZ709648A (enExample)
WO (2) WO2014093579A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5200939B2 (ja) 2005-12-23 2013-06-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 二環式ヘテロアリール化合物
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496940B (zh) * 2014-01-06 2017-03-15 广东东阳光药业有限公司 一种制备bcr‑abl抑制剂中间体的方法
CN110291081B (zh) * 2016-12-15 2023-01-31 阿瑞雅德制药公司 作为c-kit抑制剂的苯并咪唑化合物
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
KR102753323B1 (ko) * 2018-04-02 2025-01-09 스텔스 바이오테라퓨틱스 인코포레이티드 엘라미프레티드의 합성에 유용한 결정질 디펩티드
WO2019246479A1 (en) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
AU2019374142A1 (en) 2018-11-01 2021-05-27 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) * 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
AU1465301A (en) * 1999-11-08 2001-06-06 Schering Corporation Process for preparing n-(4-hydroxy-phenyl)-n'-(4'-aminophenyl)-piperazine
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
AR041992A1 (es) 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2005051366A2 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
NZ546782A (en) * 2003-12-05 2010-04-30 Biovitrum Ab Improved synthesis of 2-substituted adenosines such as spongosine
JP2007517007A (ja) 2003-12-24 2007-06-28 アストラゼネカ アクチボラグ Ｔｉｅ２（ＴＥＫ）活性を持つピリミジン
DE602004015509D1 (de) 2003-12-24 2008-09-11 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
CA2560648C (en) 2004-04-07 2013-01-22 Applied Research Systems Ars Holding N.V. 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
JP5200939B2 (ja) 2005-12-23 2013-06-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 二環式ヘテロアリール化合物
EP2024366B1 (en) 2006-05-08 2015-09-16 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
KR20090018104A (ko) 2006-05-08 2009-02-19 어리어드 파마슈티칼스, 인코포레이티드 아세틸렌계 헤테로아릴 화합물
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
US8329724B2 (en) * 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2762142A1 (en) * 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
BR112013024169A2 (pt) 2011-04-07 2016-12-06 Ariad Pharma Inc método para o tratamento e prevenção da doença de parkinson
CN103582478A (zh) * 2011-04-07 2014-02-12 阿里亚德医药股份有限公司 治疗神经退行性疾病的方法和组合物
JP2015514802A (ja) 2012-04-25 2015-05-21 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｒａｆキナーゼ媒介疾患用の方法及び組成物
CA2815506C (en) * 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
US20240083902A1 (en) 2024-03-14
US9493470B2 (en) 2016-11-15
CN105188701A (zh) 2015-12-23
CA3022250A1 (en) 2014-06-12
US20210277012A1 (en) 2021-09-09
CL2015001643A1 (es) 2015-10-02
CA3167093A1 (en) 2014-06-12
MX391445B (es) 2025-03-21
US20210024527A1 (en) 2021-01-28
MX2021002253A (es) 2021-05-27
JP2016503010A (ja) 2016-02-01
CA2815506A1 (en) 2014-06-12
US10125136B2 (en) 2018-11-13
US10662197B2 (en) 2020-05-26
MX2021002261A (es) 2021-05-27
US11192895B2 (en) 2021-12-07
CN115043843A (zh) 2022-09-13
US11192896B2 (en) 2021-12-07
MX2021002258A (es) 2021-05-27
US20210340149A1 (en) 2021-11-04
JP2026010061A (ja) 2026-01-21
US11279705B2 (en) 2022-03-22
US20190169196A1 (en) 2019-06-06
MX2021002254A (es) 2021-05-27
US20210277011A1 (en) 2021-09-09
WO2014093583A3 (en) 2014-08-07
JP7042175B2 (ja) 2022-03-25
US11384086B2 (en) 2022-07-12
MX359147B (es) 2018-09-17
US20150315194A1 (en) 2015-11-05
JP2023179498A (ja) 2023-12-19
US20210277010A1 (en) 2021-09-09
MX2015007578A (es) 2016-03-21
US11192897B2 (en) 2021-12-07
JP2018168191A (ja) 2018-11-01
MX2021002255A (es) 2021-05-27
JP6447508B2 (ja) 2019-01-09
MX2021002259A (es) 2021-05-27
WO2014093583A2 (en) 2014-06-19
WO2014093579A3 (en) 2014-07-10
US20170190707A1 (en) 2017-07-06
NZ709648A (en) 2020-05-29
MX2021002256A (es) 2021-05-27
JP7352841B2 (ja) 2023-09-29
MX2021002264A (es) 2021-05-27
MX2021002257A (es) 2021-05-27
JP2022037122A (ja) 2022-03-08
WO2014093579A2 (en) 2014-06-19
HK1218878A1 (zh) 2017-03-17

Similar Documents

Publication Publication Date Title
US11192895B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
US12291517B2 (en) Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide
AU2023219845B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US20130150450A1 (en) Novel solid forms of tacedinaline
HK40080449A (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250416

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250529